Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17821369 | 0.79 | NOS1 (0.41) | NOS1CA12CA9AHRPARP1 | |
| SCHEMBL5924246 | 0.79 | TYMS (0.51) | NOS1CA12CA9AHRPARP1 | |
| SCHEMBL9502145 | 0.79 | PARP1 (0.59) | NOS1CA12CA9AHRPARP1 | |
| SCHEMBL9305632 | 0.79 | CA12 (0.40) | CA12CA9PARP1KDM4ENPC1 | |
| SCHEMBL6139156 | 0.79 | PARP1 (0.41) | AHRPARP1ARNPC1ALDH1A1 | |
| SCHEMBL24113220 | 0.79 | MEN1 (0.41) | NOS1CA12CA9AHRPARP1 | |
| SCHEMBL8956424 | 0.79 | TDP1 (0.33) | PARP1KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL9305473 | 0.79 | ACHE (0.43) | PARP1PSMB8ARKDM4EALDH1A1 | |
| SCHEMBL20479323 | 0.79 | PDPK1 (0.43) | NOS1CA12CA9PARP1CDK9 | |
| SCHEMBL22962172 | 0.75 | KDM4E (0.45) | NOS1CA12CA9AHRPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118126467-A | Heat-resistant modified polyvinyl chloride power tube and preparation method thereof | 杭州鼎新建科实业有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-117986764-A | Flame-retardant modified polyvinyl chloride power tube and preparation method thereof | 杭州鼎新建科实业有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-111335033-A | Neckerchief fabric for infant care and preparation method thereof | 张海军 | 2020-06-26 | — | — | CN | claimed |
| US-8188254-B2 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | COLEY PHARMACEUTICAL GMBH (DE) | 2012-05-29 | — | — | US | claimed |
| CN-101454451-A | Class C oligonucleotide analogs with enhanced immunostimulatory capacity | COLEY PHARM GMBH (DE) | 2009-06-10 | — | — | CN | claimed |
| EP-1978997-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | Apollo Life Sciences Limited (AU) | 2008-10-15 | — | — | EP | claimed |
| WO-2007070983-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-06-28 | — | — | WO | claimed |
| EP-1730281-A2 | IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING IL-10 RESPONSES | Coley Pharmaceutical Group, Inc. (US) | 2006-12-13 | — | — | EP | claimed |
| EP-1728863-A2 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | Coley Pharmaceutical GmbH (DE) | 2006-12-06 | — | — | EP | claimed |
| EP-1678303-A2 | C-CLASS OLIGONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY POTENCY | Coley Pharmaceutical GmbH (DE) | 2006-07-12 | — | — | EP | claimed |
| WO-2005111057-A2 | IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING IL-10 RESPONSES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050239734-A1 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | COLEY PHARMACEUTICAL GMBH (DE) | 2005-10-27 | — | — | US | claimed |
| EP-1578954-A2 | 5' CPG NUCLEIC ACIDS AND METHODS OF USE | Coley Pharmaceutical Group, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| WO-2005042018-A2 | C-CLASS OLIGONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY POTENCY | COLEY PHARMACEUTICAL GMBH (DE) | 2005-05-12 | — | — | WO | claimed |
| US-20040171571-A1 | 5' CpG nucleic acids and methods of use | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-09-02 | — | — | US | claimed |
| WO-2004053104-A2 | 5’ CPG NUCLEIC ACIDS AND METHODS OF USE | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-06-24 | — | — | WO | claimed |
| CN-1107508-C | Process for the preparation of a composition containing 2',5'-oligoadenylic acid derivatives | UNIV TEMPLE (US) | 2003-05-07 | — | — | CN | claimed |
| US-12637646-B2 | DNA origami cell sensing platform | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2004005476-A2 | NUCLEIC ACID COMPOSITIONS FOR STIMULATING IMMUNE RESPONSES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-4594420-A | Substituted with bromine or chlorine | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637646-B2 | DNA origami cell sensing platform | DNMT3A, EPCAM, CASR | NOS1 4227/4885CA12 2049/4885CA9 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.